Magnetic Resonance Elastography of Invasive Breast Cancer: Evaluating Prognostic Factors and Treatment Response

Objectives: To assess the elasticity values in breast tissues using magnetic resonance elastography (MRE) and examine the association between elasticity values of invasive breast cancer with prognostic factors and the pathologic response to neoadjuvant systemic therapy (NST). Methods: A total of 57 patients (mean age, 54.1 years) with invasive breast cancers larger than 2 cm in diameter on ultrasound were prospectively enrolled. The elasticity values (mean, minimum, and maximum) of invasive breast cancers, normal fibroglandular tissues, and normal fat tissues were measured via MRE using a commercially available acoustic driver and compared. Elasticity values of breast cancers were compared according to prognostic factors and pathologic responses in patients who received NST before surgery. Receiver operating curve analysis was performed to evaluate the predictive efficacy of elasticity values in terms of pathological response. Results: Among the 57 patients, the mean elasticity value of invasive breast cancers was significantly higher than that of normal fibroglandular tissue and normal fat tissue (7.90 ± 5.80 kPa vs. 2.54 ± 0.80 kPa vs. 1.32 ± 0.33 kPa, all ps < 0.001). Invasive breast cancers with a large diameter (>4 cm) exhibited significantly higher mean elasticity values relative to tumors with a small diameter (≤4 cm) (11.65 ± 7.22 kPa vs. 5.87 ± 3.58 kPa, p = 0.002). Among 24 patients who received NST, mean, minimum, and maximum elasticity values significantly differed between the pathologic complete response (pCR) and non-pCR groups (all ps < 0.05). For the mean elasticity value, the area under the curve value for distinguishing pCR and non-pCR groups was 0.880 (95% confidence interval, 0.682, 0.976; p < 0.001). Conclusions: The elasticity values of invasive breast cancers measured via breast MRE showed a positive correlation with tumor size and showed potential in predicting the therapeutic response in patients receiving NST.